Evaluating treatment quality for adults with heart attacks in China
Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China
This study is trying to see how well hospitals in China are treating adults who have heart attacks to help improve their care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04088682 on ClinicalTrials.gov |
What this trial studies
This observational study investigates clinical performance and quality measures for adults experiencing acute ST-elevation myocardial infarction (STEMI) in China. It involves the annual recruitment of eligible inpatients to collect medical information and assess the performance of participating hospitals. The study aims to develop quality improvement strategies and tools that focus on enhancing treatment and clinical outcomes for STEMI patients. By comparing reperfusion rates and other performance measures annually, the study seeks to generate new knowledge about STEMI management in China.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with STEMI who arrive at the hospital within 48 hours of symptom onset.
Not a fit: Patients who do not present with STEMI or arrive at the hospital after 48 hours from symptom onset may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for patients suffering from STEMI.
How similar studies have performed: Other studies have shown success in improving clinical outcomes through quality improvement strategies in cardiovascular care, indicating that this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset. Exclusion Criteria: * None
Where this trial is running
Beijing, Beijing Municipality
- Hongjian Wang — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Zhe Zheng — Chinese Academy of Medical Sciences, Fuwai Hospital
- Study coordinator: Hongjian Wang
- Email: wanghongjianfw@hotmail.com
- Phone: 13910008985
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.